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OBJECTIVES: Since the onset of the coronavirus disease 2019 pandemic, 
immune modulators have been considered front-line candidates for the manage-
ment of patients presenting with clinical symptoms secondary to severe acute 
respiratory syndrome coronavirus 2 infection. Although heavy emphasis has been 
placed on early clinical efficacy, we sought to evaluate the impact of pharmaco-
logic approach to coronavirus disease 2019 within the ICU on secondary infec-
tions and clinical outcomes.
DATA SOURCES: PubMed (inception to March 2021) database search and 
manual selection of bibliographies from selected articles.
STUDY SELECTION AND DATA EXTRACTION: Articles relevant to corona-
virus disease 2019, management of severe acute respiratory syndrome corona-
virus 2–associated respiratory failure, and prevalence of secondary infections with 
pharmacotherapies were selected. The MeSH terms “COVID-19,” “secondary in-
fection,” “SARS-CoV-2,” “tocilizumab,” and “corticosteroids” were used for article 
identification. Articles were narratively synthesized for this review.
DATA SYNTHESIS: Current data surrounding the use of tocilizumab and/or cor-
ticosteroids for coronavirus disease 2019 management are limited given the short 
follow-up period and conflicting results between studies. Further complicating the 
understanding of immune modulator role is the lack of definitive understanding of 
clinical impact of the immune response in coronavirus disease 2019.
CONCLUSIONS: Based on the current available literature, we suggest pro-
longed trials and follow-up intervals for those patients managed with immune 
modulating agents for the management of coronavirus disease 2019.
KEY WORDS: acute respiratory failure; coronavirus disease 2019; 
immunomodulation; infectious disease; secondary infections
The report of a novel betacoronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), was first reported in Wuhan, China, in December of 2019 (1). SARS-CoV-2 and its resulting disease, corona-
virus disease 2019 (COVID-19), quickly spread worldwide, classified as a pan-
demic by the World Health Organization (WHO) in March 2020. Given the 
rapid spread and global impact, the medical community was forced to quickly 
grow and evolve to treat this novel disease. Several treatment considerations 
showed early signals of benefit in small clinical cohorts but have shown con-
flicting results in larger trials (2, 3). Many of these treatments are immuno-
modulatory and activate or suppress certain immunologic functions with the 
intent of assisting the endogenous immune response to the virus. Through 
increased knowledge regarding host response to the disease and further eval-
uation of clinical data, potential immunologic implications of both the disease 
and immunomodulatory therapies have been elucidated.
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PATHOPHYSIOLOGY AND 
IMMUNOSUPPRESSION
SARS-CoV-2 resembles the pathophysiology of se-
vere acute respiratory syndrome and Middle East res-
piratory syndrome, the two prior coronaviruses known 
to cause pneumonia, respiratory failure, and death 
(4, 5). The way by which SARS-CoV-2 invades host cells, 
resulting in profound activation of the innate immune 
system, subsequent cytokine release, and multiple organ 
failure, is shown in Figure 1 (5, 6). Elevation in blood cy-
tokine levels is a common laboratory finding in SARS-
CoV-2 patients, notably interleukin (IL)–6, IL-7, and 
IL-10 (7).
An early and strong type-1 interferon (IFN) re-
sponse is needed to suppress viral replication (8, 9). 
Type-1 IFNs constitute the largest family of IFNs in 
humans and include IFN-α, IFN-β, IFN-e, IFN-k, and 
IFN-w (10, 11). Intracellular RNA degradation, viral 
clearance, tissue repair, and extended adaptive immune 
response are key immunologic pathways facilitated by 
type-1 IFNs (12). Previous studies conducted with 
other coronavirus strains indicate these viruses ex-
hibit a potent inhibition of early type-1 IFN response 
leading to hyperinflammation, and it is theorized that 
SARS-CoV-2 also exhibits this inhibition (13–16).
As infection persists, the host immunologic state is 
characterized by immune cell apoptosis, lymphocyte dys-
function, and lymphopenia (Fig. 2). T cell response to 
SARS-CoV-2 is weakened and predisposes the host to per-
sistent immunologic impairment and progression to late-
stage infection (17). It is clear that T-cell dysfunction is a 
significant contributor to immunologic status at all stages 
of disease, leading to persistent cytokine release, inflam-
matory activation, and subsequent immunosuppression.
Increased susceptibility to secondary bacterial, fungal, 
and viral infections is a concern and has been described 
in respiratory viral infections (18). Various mechanisms 
have been implicated including endothelial cell dys-
function, vascular leakage, decreased mucus clearance, 
Figure 1. Pathophysiology of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. SARS-CoV-2 spread via 
respiratory droplets and enters the human cell via S-protein envelope binding with human angiotensin receptor-2 (hACE2). Once viral 
fusion is complete, the virus is endocytosed, and viral RNA uses host cellular components to replicate and spread. As SARS-CoV-2 
viral load peaks, the innate immune system becomes activated and a cytokine storm ensues, with release of tumor necrosis factor 
alpha (TNF-a), interferon gamma (IFN-y), granulocyte colony-stimulating factor (G-CSF), and various other interleukins (IL). Rapid 
viral replication leads to epithelial and endothelial apoptosis, vascular leakage, profound inflammation resulting in multisystem organ 
dysfunction. As infection persists, the host enters a state of immune exhaustion characterized by T-cell dysfunction, lymphopenia, and 
suppressed type-1 interferon response.
Narrative Review
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promotion of biofilm formation, and microbiome altera-
tions (18–21). Primary viral infections can also trigger re-
activation of latent viruses such as herpes simplex virus 
(HSV) or varicella zoster virus. Prolonged fever and cy-
tokine release which damage neurons and tissues where 
these viruses remain latent has led to reactivation in var-
ious inflammatory states (22). Both are common clinical 
manifestations of SARS-CoV-2 infection and may pre-
sent further risk. These mechanisms, in addition to the 
previously described immunologic dysfunction, present 
a significant risk for secondary infections in patients with 
SARS-CoV-2.
Reports of secondary bacterial infections in SARS-
CoV-2 patients vary from 4% to 25%, reaching up to 
Figure 2. Immunologic consequences of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)–associated 
immunosuppression. As infection persists, the host enters a state of immune exhaustion. A delayed or suppressed type-1 interferon 
(IFN) response leads to T-cell dysfunction and ultimately exhaustion. Furthermore, viral-induced immune cell apoptosis results in 
lymphopenia with decreases in all lymphocyte subtypes. Continued activation of the inflammatory cascade leads to increasing levels of 
inflammatory cytokines and hyperinflammation. Hyperinflammation paired with immune exhaustion places patients at an increased risk of 
secondary infectious complications. CCL = C–C motif chemokine ligand, CXCL = C-X-C motif chemokine ligand, IL = interleukin,  
NK = natural killer, TNF-a = tumor necrosis factor alpha.
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50% in nonsurvivors (23, 24). Patients admitted to 
the ICU often require mechanical ventilation or ex-
tracorporeal membrane oxygenation (ECMO), which 
present additional risk factors (25–28). Common 
bacterial pathogens include Staphylococcus aureus, 
Pseudomonas aeruginosa, and Enterococcus species. 
Data on fungal secondary infections are less abundant 
compared with bacterial infections, but Candida spe-
cies appear to be the most common fungal pathogen 
encountered (29). There are also increasing reports 
of SARS-CoV-2–associated pulmonary aspergillosis 
similar to that seen with previous influenza outbreaks 
(30–33). However, larger studies are conflicting on the 
true prevalence and risk of fungal secondary infec-
tions in this population (34–36). Regarding viral sec-
ondary infections, previously reported rates of HSV 
reactivation range from 21% to 57% in ICU patients 
(37, 38). Only one study has specifically evaluated 
the frequency of HSV reactivation in SARS-CoV-2 
patients and found a reactivation rate of 23.6% (39). 
Although the immunologic effects of SARS-CoV-2 im-
pose risks for secondary infections, utilization of treat-
ment modalities with immunosuppressive properties, 
such as tocilizumab and corticosteroids, may confer 
additional risk.
Tocilizumab is a recombinant, humanized mono-
clonal antibody that competitively antagonizes both 
soluble and membrane-bound IL-6 receptors, prevent-
ing IL-6 signal transduction and leading to significant 
immunosuppression (40). Current literature suggests 
tocilizumab may reduce the need or duration of me-
chanical ventilation, progression to severe disease, or 
death, but results are inconsistent (2, 3, 41–44). Reports 
of infectious complications in SARS-CoV-2 patients 
treated with tocilizumab are also inconsistent and lim-
ited in follow-up compared with previous tocilizumab 
trials (45–47).
Additionally, corticosteroids possess potent im-
munosuppressant properties, and infectious compli-
cations have been well-documented with use of oral 
corticosteroids for rheumatologic conditions (48–50). 
The effect is dose-dependent, with every increase of 
5 mg daily of prednisone and 1,000 mg cumulative 
dose in the last year increasing the risk of all-cause in-
fection by 13% and 50%, respectively. Even short-term 
use of prednisone has demonstrated a higher risk of 
sepsis within 30 days of initiation (50). Similar find-
ings have been documented in critically ill patients 
receiving corticosteroids, with significant increases in 
pneumonia (odds ratio [OR], 2.64; CI, 1.21–5.75) and 
bacteremia (OR, 3.25; CI, 1.26–8.37) (51).
Considering the associations with infection previ-
ously reported with tocilizumab and corticosteroid 
administration, these therapies may pose similar risks 
following their use in patients with SARS-CoV-2. The 
aim of this study was to characterize the incidence of 
secondary infections in patients with SARS-CoV-2 
infection admitted to a single-center ICU. We also 
provide an in-depth review of the available literature 
regarding secondary infections following tocilizumab 
and corticosteroid therapy in SARS-CoV-2 patients.
METHODS
This was a retrospective case series conducted at 
University of Kentucky Healthcare, which is a tertiary 
care referral academic medical center. This study was 
approved by the University of Kentucky HealthCare 
Institutional Review Board (approval number 47751). 
Due to the retrospective nature, informed consent was 
waived. The electronic health record for patients admit-
ted to the medical ICU at our institution with a positive 
SARS-CoV-2 test from March 2020 to November 2020 
was reviewed. Data including baseline demographics, 
clinical variables, and outcomes including secondary 
infections were collected in a standardized data collec-
tion form. Baseline immunosuppression was defined 
as presence of functional immunosuppressive disor-
ders, autoimmune disorders, or home medications 
with known immunosuppressive properties prior to 
admission.
Secondary infections were defined as a new infec-
tion with onset greater than 48 hours from initial ICU 
admission, including ICUs at outside hospitals. These 
infections were identified via microbiologic results 
positive for new bacterial, viral, and fungal pathogens 
requiring anti-infective implementation. In addition 
to the aforementioned criteria, fungal secondary infec-
tions were also identified based on an elevated beta-
D-glucan (BDG) that was treated with an antifungal 
agent. Viral secondary infections were identified 
based on a positive polymerized chain reaction test. 
Treatment variables were found via the medication ad-
ministration record. Cases were adjudicated by review 
of the primary team notes and treatment decisions. 
Candida species that grew in the urinary or respiratory 
Narrative Review
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tract and coagulase-negative Staphylococcus blood cul-
tures which were deemed noninfectious by the treating 
team were not included.
The authors also conducted a MEDLINE/PubMed 
database search from inception to April 2021, and 
bibliographies were manually selected from selected 
articles. The MeSH terms “COVID-19,” “secondary 
infection,” SARS-CoV-2,” “tocilizumab,” and “cortico-
steroids” were used for article identification. Articles 
relevant to COVID-19, management of SARS-CoV-
2–associated respiratory failure, and incidence of 
secondary infections with pharmacotherapies were 
selected. Articles were narratively synthesized for this 
review.
RESULTS
Over a period of 6 months, we analyzed 237 patients 
who presented to the ICU with SARS-CoV-2 com-
plicated by acute respiratory failure (Table 1). On av-
erage, patients in our case series were elderly, obese, 
and more than 60% were diagnosed with diabetes 
prior to admission (Table  1). One-hundred eleven 
patients (46.8%) were transferred from an outside hos-
pital where they had been admitted for an average of 7 
days before transfer. Baseline immunosuppression was 
present in 87 patients (36.7%). The need for mechan-
ical ventilation was high at 75%, whereas ECMO was 
used in 12.7% of patients. Tocilizumab use was infre-
quent; however, corticosteroids were administered to 
a majority of patients. In those patients who received 
tocilizumab, only three (10%) did not receive concom-
itant corticosteroids. There were 18 patients who did 
not receive tocilizumab or dexamethasone during ICU 
admission. Seventy-six patients (32.1%) died during 
their admission, and the majority died while in the 
ICU. Overall, our patients experienced ICU and hos-
pital lengths of stay of 16 ± 16 days and 24 ± 18 days, 
respectively.
Of the 237 patients included in this case series, 
110 (46.4%) developed a secondary infection, and a 
total of 173 secondary infections were identified. In 
patients with a secondary infection, 55 (50%) had one 
secondary infection, 31 (23.2%) had two secondary 
infections, 14 (12.7%) had three secondary infections, 
and 10 (9.1%) had four or more secondary infec-
tions (Table  1). Respiratory (49%) and bloodstream 
(27.6%) were the most common sources of infection 
(Supplementary Table 1, http://links.lww.com/CCX/
A717). Common respiratory pathogens included both 
Gram-positive and Gram-negative organisms, whereas 
bloodstream pathogens were mainly Gram-positive 
organisms. Regarding fungal secondary infections, 
most were identified as Candida species or an elevated 
BDG treated with an antifungal agent. Only one case of 
aspergillus was identified in a respiratory culture. The 
only virial secondary infection identified was HSV re-
activation which occurred in 17 patients (7.2%).
Patients developing secondary infections had higher 
rates of baseline immunosuppression, diabetes, need 
for ventilator and ECMO support, and vasopressor use. 
These patients also experienced greater rates of rein-
tubation, longer ICU and hospital lengths of stay, and 
higher mortality rates. Of the 30 patients who received 
tocilizumab, 11 (36.7%) experienced a secondary in-
fection. Notably, of the three patients who received 
tocilizumab monotherapy, no incidences of secondary 
infection were seen. Additionally, 213 patients (89.9%) 
received corticosteroids, and 106 (49.8%) developed a 
secondary infection. All patients who had HSV reac-
tivation received corticosteroids during their ICU ad-
mission. Of the 27 patients who received tocilizumab 
in combination with corticosteroids, 11 (40.7%) de-
veloped secondary infections. In those patients not 
receiving corticosteroids or tocilizumab, fours (22%) 
developed a secondary infection. Supplemental Table 2 
(http://links.lww.com/CCX/A718) further summa-
rizes the incidence of secondary infections by thera-
peutic intervention.
DISCUSSION AND REVIEW OF 
LITERATURE
Case Series
Our findings suggest a high prevalence of secondary 
infections in patients with SARS-CoV-2, especially 
bacterial pneumonia and bloodstream infections. 
In our study, 46.4% of patients developed secondary 
infections compared with 4–25% previously reported 
(23). The higher prevalence reported in our study may 
reflect the vast differences in patient populations. In 
our case series, more than 60% of patients were diag-
nosed with diabetes prior to admission, whereas pre-
vious reports had a much lower incidence of diabetes 
ranging from 16.3% to 22.6% (30). Previous studies 
have shown those with diabetes are three times more 
Behal et al
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TABLE 1. 
Demographics and Outcomes of Patient Population
Variables
No Secondary  
Infection (N = 127)
Secondary  
Infection (N = 110)
Overall  
(N = 237)
Age, yr, mean, sd 62.1, 14.2 58.9, 13.3 61, 14
Female gender, n (%) 74 (58.3) 67 (60.9) 96 (40.5)
Body mass index, kg/m2, mean, sd 33.9, 7.9 35.9, 11.2 34.8, 9.6
Immunosuppression at baseline, n (%)a 37 (29.1) 50 (45.5) 87 (36.7)
Diabetes, n (%) 72 (56.7) 73 (66.4) 145 (61.2)
Source, OSH, n (%) 52 (40.9) 59 (53.6) 111 (46.8)
OSH duration prior to transfer, days, mean, sd 5.4, 4.4 8.9, 6.8 7.3, 6.0
Source, floor, n (%) 1 (0.8) 0 (0) 20 (8.4)
Source, emergency department, n (%) 58 (45.7) 38 (34.5) 96 (40.5)
Source, long-term acute care facility/nursing home, n (%) 5 (3.9) 5 (4.5) 10 (4.2)
Days since onset, mean, sd 8.6, 5.7 9.7, 6.7 9.1, 6.2
Mechanical ventilation, n (%) 76 (59.8) 103 (93.6) 179 (75.5)
Extracorporeal membrane oxygenation, n (%) 9 (7.0) 21 (19.1) 30 (12.7)
Reintubation, n (%) 5 (3.9) 18 (16.4) 23 (9.7)
ICU mortality, n (%) 26 (20.5) 47 (42.7) 73 (30.8)
Hospital mortality, n (%) 28 (22.1) 48 (43.6) 76 (32.1)
ICU readmission, n (%) 3 (2.4) 5 (4.5) 8 (3.4)
Hospital duration, d, mean, sd 19.3, 16.1 28.7, 18.2 23.61, 17.73
ICU duration, d, mean, sd 11.7, 13.3 21.7, 17.0 16.31, 15.94
Maximum C-reactive protein, mg/L, mean, sd 516.9, 516.6 240.5, 133.8 228.1, 385.4
Maximum d-dimer, µg/mL, mean, sd 4.6, 5.6 4.7, 5.1 4.651, 5.4
Maximum interleukin-6, pg/mL, mean, sd 79.7, 77.6 49.9, 113.3 65, 95
Minimum platelets, k/mc, mean, sd 177.3, 68.4 134.1, 61.8 157, 68.7
Minimum WBC, k/mc, mean, sd 6.6, 4.3 6.8, 5.0 6.69, 4.64
Number of infections, n (%)    
 One — 55 (50) 55 (23.2)
 Two — 31 (25.2) 31(13.1)
 Three — 14 (12.7) 14 (5.9)
 Four or more — 10 (9.1) 10 (4.2)
Renal replacement therapy, n (%) 20 (15.8) 42 (38.2) 62 (26.2)
Vasopressor, n (%) 56 (44.1) 95 (86.4) 151 (63.7)
Steroids, n (%) 107 (84.3) 106 (96.4) 213 (89.9)
Remdesivir, n (%) 77 (60.6) 71 (64.5) 148 (62.5)
Tocilizumab, n (%) 19 (15.0) 11 (10) 30 (12.7)
Hydroxychloroquine, n (%) 10 (7.9) 7 (6.4) 17 (7.2)
— = not applicable, OSH = outside hospital.
aDefined as receiving immunosuppressive therapies or presence of immunosuppressive disease state prior to admission.
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likely to develop bacterial infections due to defective 
phagocytes (52, 53). Additionally, immunomodula-
tory treatment with steroids was higher in our case se-
ries (30). Our case series focused only on a medical 
ICU population, whereas previous reports included 
patients outside of the ICU (30).
In a recent analysis, authors report the differences 
in the immune response between COVID-19 and 
bacterial sepsis (54). Immune cell profiles differed 
between mild and severe COVID-19 patients with se-
verity being associated with unique immune profiles 
compared with sepsis, with persistent and profound 
depletion in lymphocyte subsets as well as reduc-
tion in human leukocyte antigen-DR on circulating 
monocytes expression. Findings supported the onset 
of strong and durable immune suppression together 
with an elevated incidence of ICU-acquired infections 
of 60% in those with COVID-19. Thus, using immuno-
modulating therapies in the treatment of SARS-CoV-2 
might impact ICU-acquired infections, which supports 
our findings of increased risk of secondary infections 
in patients receiving corticosteroids or tocilizumab. 
Rates of HSV reactivation in our population were 7.2% 
which is much lower than 23.6% reported by the only 
published study specifically looking at this outcome 
(39). As previously mentioned, tocilizumab and corti-
costeroids exhibit immunosuppressive effects that can 
contribute to the development of secondary infections. 
We now present a review of the available literature on 
secondary infections associated with tocilizumab and 
corticosteroid use in SARS-CoV-2 patients. To our 
knowledge, this is the only expansive review of sec-
ondary infections with these two immunomodulatory 
therapies in SARS-CoV-2 patients.
Tocilizumab
A summary of studies reporting secondary infections 
in SARS-CoV-2 patients treated with tocilizumab is 
presented in Supplementary Table 3 (http://links.lww.
com/CCX/A719). In small studies, tocilizumab has 
been associated with a 16–54% incidence of secondary 
infections (24, 55–62). In a large study of 3,580 patients 
with SARS-CoV-2, 497 patients received tocilizumab 
and were four times as likely to develop secondary infec-
tions compared with standard of care (63). However, 
two prospective, randomized, double-blind, placebo-
controlled trials investigating tocilizumab compared 
with standard of care did not report a significant differ-
ence in secondary infections between groups (64, 65). 
The most recently published randomized trials also 
found no difference in bacterial secondary infections 
in patients treated with tocilizumab compared with 
standard of care; however, nonsevere secondary infec-
tions were not included. 43, 44, 66). It should be noted, 
the definition of secondary infection was not reported 
for a majority of these previous trials. For studies pro-
viding a definition, secondary infections were most 
commonly identified based on positive microbiologic 
cultures. Follow-up duration also varied significantly 
among studies ranging from 10 to 47 days, with some 
studies not reporting a follow-up duration.
Tocilizumab use was less frequent in our study 
compared with prior studies, and this could be largely 
due to our study period as this was conducted prior to 
many of the large, randomized, controlled trials show-
ing efficacy of tocilizumab. However, our secondary 
infection rate of 36.7% following tocilizumab use is in 
line with rates previously reported.
Although much less reported in current literature, 
viral reactivation has also been described follow-
ing administration of tocilizumab. HSV reactivation 
was noted in one patient from a small cohort study, 
whereas another study reported one patient with hep-
atitis B virus reactivation and four patients with HSV 
reactivation (55, 58). Similar results were seen in our 
population with only two patients experiencing HSV 
reactivation who received tocilizumab, further sup-
porting a potential low risk for viral reactivation fol-
lowing tocilizumab therapy in SARS-CoV-2 patients. 
In patients with rheumatoid arthritis, a Japanese post-
marketing registry estimated the rate of HSV to be 
2.2 episodes per 100 patient-years, and in the United 
States, this was conducted using U.S. Medicare data 
with the incidence of HSV of 2.15 episodes per 100 
patient-years with no differences compared with other 
biologics (67, 68).
It is unclear how long the immunosuppressive effects 
persist after single or subsequent doses of tocilizumab 
and may lead to infectious complications later during 
the hospital course. A 2011 meta-analysis reported a 
rate of serious infection of 4.9 per 100 patient-years 
among patients receiving tocilizumab doses of 8 mg/kg 
and lower for those receiving placebo or 4 mg/kg (3.5 
per 100 patient-years) in a rheumatoid arthritis long-
term safety analysis (69). The type of infection ranged 
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from pneumonia, urinary tract infections, and cellu-
litis. Those who were older than 65 years old reached 
an incident rate of 8.5 episodes per 100 patient-years. 
Authors found the rate of serious infections remained 
relatively stable with continued tocilizumab treatment; 
thus, the potential to impact rates of serious infection is 
likely due to tocilizumab’s rapid onset of action leading 
to reductions of inflammatory markers with prompt 
suppression of inflammation. Furthermore, in adult 
patients with rheumatoid arthritis, the half-life ranges 
from 11 to 13 days (70). In clinical trials of rheuma-
toid arthritis, tocilizumab has been administered once 
every 4 weeks. Considering the risk of secondary infec-
tions and the apparent half-life of tocilizumab, it is log-
ical to consider the need for long-term infection risk 
follow-up in patients receiving tocilizumab in the set-
ting of COVID-19. In our case series, the overall hos-
pital duration was 23.6 days. Considering the half-life 
of tocilizumab, our case series likely did not capture 
the true incidence of secondary infections attributed 
to tocilizumab, and longer duration of follow-up is 
needed. Additionally, lack of standardized dosing strat-
egies for tocilizumab further complicates interpretation 
of secondary infection rates following administration.
Corticosteroids
Corticosteroids have emerged as a front-line treatment 
option for SARS-CoV-2, but despite the proposed ef-
ficacy, safety data on corticosteroids in SARS-CoV-2 
remain unclear. The largest randomized trial of corti-
costeroids in SARS-CoV-2 to date, RECOVERY, failed 
to report the incidence of adverse events, including sec-
ondary infections (71). Furthermore, after the results 
of RECOVERY were published, additional trials were 
terminated early because equipoise for withholding 
corticosteroids was no longer present, further limiting 
the analysis of secondary infections. The incidence and 
risk of secondary infections remains unclear and is of 
great concern in the context of SARS-CoV-2 infection.
A summary of studies reporting secondary infections 
in SARS-CoV-2 patients treated with corticosteroids is 
presented in Table 2. Of the available studies, minimal 
to no increase in risks of secondary bacterial or fungal 
infections has been found after 28 days of follow-up, 
regardless of the steroid used (dexamethasone, hydro-
cortisone, and methylprednisolone) (72–74). Although 
findings were not statistically significant, most of these 
studies were terminated early or largely underpowered. 
Additionally, these studies had varying definitions and 
methods of detecting secondary infections ranging 
from positive microbiological cultures to physician dis-
cretion and use of antibiotic therapy. Corticosteroid 
use was common in our study population (89.9%) and 
reflects the published literature supporting efficacy of 
corticosteroids that became available during our study 
period. Overall, 49.8% of patients who received corti-
costeroids developed at least one secondary infection 
in our population, and this is higher than previously 
published rates ranging from 21.9% to 37.7% (72, 73). 
This could be due to the longer duration of follow-up 
to death or hospital discharge performed in our study 
than was done in previous studies.
Reactivation of latent viral infections has been 
described with corticosteroid use in the setting of 
SARS-CoV-2 infection. Although overall HSV reactiv-
ation rate was low (7.2%) in our study population, all 
patients experiencing HSV reactivation received cor-
ticosteroids. Limited data are available on viral reac-
tivation following corticosteroid use in SARS-CoV-2 
infection; however, the observed rate in our study is 
much higher than previously reported. In a retro-
spective study of 38 ICU patients who experienced 
Herpesviridae pulmonary reactivations, 44% in the 
reactivation group received corticosteroids compared 
with only 20% in the nonreactivation group (39). 
Although not statistically significant, the clinical sig-
nificance of Herpesviridae reactivation in patients with 
corticosteroids should raise concern given the preva-
lence of this disease largely arises in immunocompro-
mised hosts and may lead to fatal outcomes. Recently, 
Kuindersma et al (75) proposed tailoring immune 
modulation rather than targeting inflammation with 
corticosteroids in all COVID-19 patients. They suggest 
using variables such as fever, heart rate, CRP, and mi-
crobiological workup to help address whether steroids 
should be initiated, changed, or stopped. This sugges-
tion stems from the concern of patients becoming more 
susceptible to secondary infections following the uti-
lization of corticosteroids. Authors found that within 
the first wave of COVID-19 between March and May 
2020, 2% of patients were diagnosed with HSV pneu-
monitis, and during the second wave from September 
to November 2020, 19% of patients were diagnosed 
with HSV pneumonitis. They suggest this difference in 
HSV pneumonitis may be due to the stark contrast of 
Narrative Review
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TABLE 2. 






















28 d Not reported 88.1% vs 86.5% were 
receiving other con-
comitant antibiotics
CoDEX 299 ICU patients Dose: 20 mg × 5 d, 
then 10 mg × 5 d
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9.5%
  Trial halted early
 151 (51%) 
received 
dexamethasone
Duration: 10 d or 
until ICU dis-
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28 d At discretion of 
provider and 
must have been 
treated with 
antibiotics
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8 d taper if respi-
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improved by day 4
CAPE 
COVID
149 ICU patients Dose: 200 mg/d × 
7 d, 100 mg/d 
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× 3 d
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hydrocortisone
Duration: 14 d     
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44% vs 20% received 
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 38 mechanically 
ventilated 
patients
     
BSI = bloodstream infection.
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corticosteroid recommendations in early versus later 
phases of COVID-19.
Given the imprecisions of the data, the WHO 
recommends corticosteroids with low certainty in 
SARS-CoV-2 by extrapolating evidence from acute 
respiratory distress syndrome, pneumonia, and sepsis 
studies and continues to suggest the risk of secondary 
infections in these conditions is low (risk ratio, 1.01; 
CI, 0.9–1.13) (76).
LIMITATIONS AND FUTURE 
DIRECTIONS
Several limitations in our case series should be ac-
knowledged, namely the single-center, retrospective 
design. Additionally, our overall sample size was 
relatively small. We also did not assess the associa-
tion of secondary infections with clinical outcomes 
in our study; however, it is logical that secondary 
infectious complications would contribute to poor 
clinical outcomes. Secondary bacterial, fungal, and 
viral infections can be common among patients with 
SARS-CoV-2 due to disease pathophysiology as well 
as immunosuppressive therapies. Additional stud-
ies are needed to establish the impact of secondary 
infections on clinical prognosis and outcomes in 
patients with SARS-CoV-2. Several risk factors for 
contracting SARS-CoV-2 and developing severe di-
sease have been identified (77, 78). Risk factors for 
developing secondary infections following immuno-
suppressive therapies for SARS-CoV-2 may certainly 
exist; however, identification is lacking at this time. 
Future studies working to identify such risk factors 
may help select patients who require closer monitor-
ing for infection following treatment or patients in 
which certain immunosuppressive therapies should 
be avoided. If immunosuppressive therapies such 
as tocilizumab or corticosteroids are used, clini-
cians should vigilantly monitor for the develop-
ment of secondary infections following treatment. 
Unfortunately, little is known regarding the chron-
ological association between immunosuppressive 
therapies and secondary infections in patients with 
SARS-CoV-2. Future studies should aim to charac-
terize the timeline of developing secondary infec-
tions in patients with SARS-CoV-2 who are treated 
with tocilizumab, corticosteroids, or other immuno-
suppressive therapies to aid in infection surveillance 
and reporting.
CONCLUSIONS
Secondary infections occur frequently in ICU patients 
being treated for SARS-CoV-2 infection, with tocili-
zumab and corticosteroid exposure potentially increas-
ing risk. Future studies are needed with long-term 
follow-up of clinical outcomes to identify risk factors 
and mitigation strategies of secondary infections in 
patients with SARS-CoV-2 treated with these therapies.
ACKNOWLEDGMENTS
We thank Dr. Jamie Sturgill (University of Kentucky, 
College of Medicine, Department of Pulmonary, 
Critical Care, and Sleep Medicine) for her help with 
article revision.
 1 Department of Pharmacy Practice, University of Kentucky, 
College of Pharmacy, Lexington, KY.
 2 Department of Pulmonary, Critical Care, and Sleep Medicine, 
University of Kentucky, College of Medicine, Lexington, KY.
Supplemental digital content is available for this article. Direct 
URL citations appear in the printed text and are provided in the 
HTML and PDF versions of this article on the journal’s website 
(http://journals.lww.com/ccejournal).
The authors have disclosed that they do not have any conflicts 
of interest.
For information regarding this article, E-mail: brittany.bissell@uky.
edu
REFERENCES
 1. Solomon CG, Gandhi RT, Lynch JB, et al: Mild or moderate 
COVID-19. N Engl J Med 2020; 18:1757–1766
 2. Gordon A, Mouncey P, Al-Beidh F: Interleukin-6 receptor 
antagonists in critically ill patients with Covid-19. N Engl J Med 
2021; 384:1491–1502
 3. Rosas IO, Bräu N, Waters M, et al: Tocilizumab in hospital-
ized patients with severe Covid-19 pneumonia. N Engl J Med 
2021; 384:1503–1516
 4. Zhou P, Yang XL, Wang XG, et al: A pneumonia outbreak as-
sociated with a new coronavirus of probable bat origin. Nature 
2020; 579:270–273
 5. Zhao Y, Zhao Z, Wang Y, et al: Single-cell RNA expression pro-
filing of ACE2, the receptor of SARS-CoV-2. bioRxiv. Published 
online April 9, 2020. doi: 10.1101/2020.01.26.919985
 6. Shang J, Ye G, Shi K, et al: Structural basis of receptor recog-
nition by SARS-CoV-2. Nature 2020; 581:221–224
 7. Huang C, Wang Y, Li X, et al: Clinical features of patients 
infected with 2019 novel coronavirus in Wuhan, China. Lancet 
2020; 395:497–506
 8. Channappanavar R, Fehr AR, Zheng J, et al: IFN-I response 
timing relative to virus replication determines MERS corona-
virus infection outcomes. J Clin Invest 2019; 129:3625–3639
Narrative Review
Critical Care Explorations www.ccejournal.org     11
 9. Cervantes-Barragán L, Kalinke U, Züst R, et al: Type I IFN-mediated 
protection of macrophages and dendritic cells secures control of 
murine coronavirus infection. J Immunol 2009; 182:1099–1106
 10. Schneider WM, Chevillotte MD, Rice CM: Interferon-stimulated 
genes: A complex web of host defenses. Annu Rev Immunol 
2014; 32:513–545
 11. Uzé G, Schreiber G, Piehler J, et al: The receptor of the type I 
interferon family. In: Interferon: The 50th Anniversary. Vol. 316. 
Berlin, Germany, Springer, 2007, pp 71–95
 12. Crouse J, Kalinke U, Oxenius A: Regulation of antiviral T 
cell responses by type I interferons. Nat Rev Immunol 2015; 
15:231–242
 13. Rose KM, Elliott R, Martínez-Sobrido L, et al: Murine corona-
virus delays expression of a subset of interferon-stimulated 
genes. J Virol 2010; 84:5656–5669
 14. Zhao L, Jha BK, Wu A, et al: Antagonism of the interferon-
induced OAS-RNase L pathway by murine coronavirus ns2 
protein is required for virus replication and liver pathology. Cell 
Host Microbe 2012; 11:607–616
 15. Totura AL, Baric RS: SARS coronavirus pathogenesis: Host 
innate immune responses and viral antagonism of interferon. 
Curr Opin Virol 2012; 2:264–275
 16. Lokugamage K, Hage A, de Vries M, et al: Type I inter-
feron susceptibility distinguishes SARS-CoV-2 from 
SARS-CoV. bioRxiv. Published online July 13, 2020. doi: 
10.1101/2020.03.07.982264
 17. Huang Y, Chen S, Yang Z, et al: SARS-CoV-2 viral load in clin-
ical samples from critically ill patients. Am J Respir Crit Care 
Med 2020; 201:1435–1438
 18. Bakaletz LO: Viral-bacterial co-infections in the respiratory 
tract. Curr Opin Microbiol 2017; 35:30–35
 19. Vareille M, Kieninger E, Edwards MR, et al: The airway ep-
ithelium: Soldier in the fight against respiratory viruses. Clin 
Microbiol Rev 2011; 24:210–229
 20. Avadhanula V, Rodriguez CA, Devincenzo JP, et al: Respiratory 
viruses augment the adhesion of bacterial pathogens to res-
piratory epithelium in a viral species- and cell type-dependent 
manner. J Virol 2006; 80:1629–1636
 21. Hanada S, Pirzadeh M, Carver KY, et al: Respiratory viral infec-
tion-induced microbiome alterations and secondary bacterial 
pneumonia. Front Immunol 2018; 9:2640
 22. Dewals BG, Machiels B, Liang X, et al: “Novel” triggers of her-
pesvirus reactivation and their potential health relevance. Front 
Microbiol 2019; 1:3207
 23. Garcia-Vidal C, Sanjuan G, Moreno-García E, et al; COVID-19 
Researchers Group: Incidence of co-infections and superin-
fections in hospitalized patients with COVID-19: A retrospec-
tive cohort study. Clin Microbiol Infect 2021; 27:83–88
 24. Giacobbe DR, Battaglini D, Ball L, et al: Bloodstream infections 
in critically ill patients with COVID-19. Eur J Clin Invest 2020; 
50:e13319
 25. Lansbury L, Lim B, Baskaran V, et al: Co-infections in people 
with COVID-19: A systematic review and meta-analysis. J 
Infect 2020; 81:266–275
 26. Chen X, Zhao B, Qu Y, et al: Detectable serum SARS-CoV-2 
viral load (RNAaemia) is closely correlated with drastically 
elevated interleukin 6 (IL-6) level in critically ill COVID-19 
patients. Clin Infect Dis 2020; 6:ciaa449
 27. Luyt CE, Sahnoun T, Gautier M, et al: Ventilator-associated 
pneumonia in patients with SARS-CoV-2-associated acute 
respiratory distress syndrome requiring ECMO: A retrospec-
tive cohort study. Ann Intensive Care 2020; 10:158
 28. Razazi K, Arrestier R, Haudebourg AF, et al: Risks of ventilator-
associated pneumonia and invasive pulmonary aspergillosis in 
patients with viral acute respiratory distress syndrome related 
or not to Coronavirus 19 disease. Crit Care 2020; 24:699
 29. Hughes S, Troise O, Donaldson H, et al: Bacterial and fungal 
coinfection among hospitalized patients with COVID-19: A 
retrospective cohort study in a UK secondary-care setting. Clin 
Microbiol Infect 2020; 26:1395–1399
 30. Schauwvlieghe AFAD, Rijnders BJA, Philips N, et al; Dutch-
Belgian Mycosis study group: Invasive aspergillosis in patients 
admitted to the intensive care unit with severe influenza: A ret-
rospective cohort study. Lancet Respir Med 2018; 6:782–792
 31. Arastehfar A, Carvalho A, van de Veerdonk FL, et al: COVID-
19 associated pulmonary aspergillosis (CAPA)—from immu-
nology to treatment. J Fungi (Basel) 2020; 6:91
 32. van Arkel ALE, Rijpstra TA, Belderbos HNA, et al: COVID-19-
associated pulmonary aspergillosis. Am J Respir Crit Care Med 
2020; 202:132–135
 33. Koehler P, Cornely OA, Böttiger BW, et al: COVID-19 associ-
ated pulmonary aspergillosis. Mycoses 2020; 63:528–534
 34. Fekkar A, Lampros A, Mayaux J, et al: Occurrence of invasive 
pulmonary fungal infections in severe COVID-19 patients admit-
ted to the ICU. Am J Respir Crit Care Med 2020; 203:307–317
 35. Pemán J, Ruiz-Gaitán A, García-Vidal C, et al: Revista 
Iberoamericana de Micología fungal co-infection in COVID-19 
patients: Should we be concerned? Rev Iberoam Micol 2020; 
37:41–46
 36. White PL, Dhillon R, Cordey A, et al: A national strategy to diag-
nose coronavirus disease 2019–associated invasive fungal di-
sease in the intensive care unit. Clin Infect Dis 2020:ciaa1298
 37. Luyt CE, Combes A, Deback C, et al: Herpes simplex virus lung 
infection in patients undergoing prolonged mechanical ventila-
tion. Am J Respir Crit Care Med 2007; 175:935–942
 38. Saugel B, Jakobus J, Huber W, et al: Herpes simplex virus 
in bronchoalveolar lavage fluid of medical intensive care unit 
patients: Association with lung injury and outcome. J Crit Care 
2016; 32:138–144
 39. Le Balc’h P, Pinceaux K, Pronier C, et al: Herpes simplex virus 
and cytomegalovirus reactivations among severe COVID-19 
patients. Crit Care 2020; 24:530
 40. Hardy A: Genentech Inc. Actemra (tocilizumab) Injection Package 
Insert. South San Francisco, CA, Genentech Inc, 2018, pp 1–40
 41. Lan SH, Lai CC, Huang HT, et al: Tocilizumab for severe 
COVID-19: A systematic review and meta-analysis. Int J 
Antimicrob Agents 2020; 56:106103
 42. Aziz M, Haghbin H, Abu Sitta E, et al: Efficacy of tocilizumab 
in COVID-19: A systematic review and meta-analysis. J Med 
Virol 2021; 93:1620–1630
 43. Stone JH, Frigault MJ, Serling-Boyd NJ, et al; BACC Bay 
Tocilizumab Trial Investigators: Efficacy of Tocilizumab in Patients 
Hospitalized with Covid-19. N Engl J Med 2020; 383:2333–2344
 44. Salama C, Han J, Yau L, et al: Tocilizumab in patients hos-
pitalized with covid-19 pneumonia. N Engl J Med 2021; 
384:20–30
Behal et al
12     www.ccejournal.org July 2021 • Volume 3 • Number 7
 45. Calderón-Goercke M, Loricera J, Aldasoro V, et al: Tocilizumab 
in giant cell arteritis. Observational, open-label multicenter 
study of 134 patients in clinical practice. Semin Arthritis Rheum 
2019; 49:126–135
 46. Yamamoto K, Goto H, Hirao K, et al: Longterm safety of tocili-
zumab: Results from 3 years of followup postmarketing sur-
veillance of 5573 patients with rheumatoid arthritis in Japan. J 
Rheumatol 2015; 42:1368–1375
 47. Chiu YM, Chen DY: Infection risk in patients undergoing treat-
ment for inflammatory arthritis: Non-biologics versus biologics. 
Expert Rev Clin Immunol 2020; 16:207–228
 48. Coutinho AE, Chapman KE: The anti-inflammatory and immu-
nosuppressive effects of glucocorticoids, recent developments 
and mechanistic insights. Mol Cell Endocrinol 2011; 335:2–13
 49. Wu J, Keeley A, Mallen C, et al: Incidence of infections asso-
ciated with oral glucocorticoid dose in people diagnosed with 
polymyalgia rheumatica or giant cell arteritis: A cohort study in 
England. CMAJ 2019; 191:E680–E688
 50. Waljee AK, Rogers MAM, Lin P, et al: Short term use of oral 
corticosteroids and related harms among adults in the United 
States: Population based cohort study. BMJ 2017; 357:j1415
 51. Britt RC, Devine A, Swallen KC, et al: Corticosteroid use 
in the intensive care unit: At what cost? Arch Surg 2006; 
141:145–149
 52. Joshi N, Caputo GM, Weitekamp MR, et al: Infections in patients 
with diabetes mellitus. N Engl J Med 1999; 341:1906–1912
 53. Martin GS, Mannino DM, Eaton S, et al: The epidemiology of 
sepsis in the United States from 1979 through 2000. N Engl J 
Med 2003; 348:1546–1554
 54. de Roquetaillade C, Mansouri S, Brumpt C, et al: Comparison 
of circulating immune cells profiles and kinetics between co-
ronavirus disease 2019 and bacterial sepsis. Crit Care Med 
2021 May 18. [online ahead of print]
 55. Alattar R, Ibrahim TBH, Shaar SH, et al: Tocilizumab for the 
treatment of severe coronavirus disease 2019. J Med Virol 
2020; 92:2042–2049
 56. Campochiaro C, Della-Torre E, Cavalli G, et al; TOCI-RAF Study 
Group: Efficacy and safety of tocilizumab in severe COVID-
19 patients: A single-centre retrospective cohort study. Eur J 
Intern Med 2020; 76:43–49
 57. Vu CA, DeRonde KJ, Vega AD, et al: Effects of tocilizumab 
in COVID-19 patients: A cohort study. BMC Infect Dis 2020; 
20:964
 58. Guaraldi G, Meschiari M, Cozzi-Lepri A, et al: Tocilizumab in 
patients with severe COVID-19: A retrospective cohort study. 
Lancet Rheumatol 2020; 2:e474–e484
 59. Biran N, Ip A, Ahn J, et al: Tocilizumab among patients with 
COVID-19 in the intensive care unit: A multicentre observa-
tional study. Lancet Rheumatol 2020; 2:e603–e612
 60. Toniati P, Piva S, Cattalini M, et al: Tocilizumab for the treat-
ment of severe COVID-19 pneumonia with hyperinflamma-
tory syndrome and acute respiratory failure: A single center 
study of 100 patients in Brescia, Italy. Autoimmun Rev 2020; 
19:102568
 61. Rossotti R, Travi G, Ughi N, et al; Niguarda COVID-19 Working 
Group: Safety and efficacy of anti-il6-receptor tocilizumab use 
in severe and critical patients affected by coronavirus disease 
2019: A comparative analysis. J Infect 2020; 81:e11–e17
 62. Somers EC, Eschenauer GA, Troost JP, et al: Tocilizumab for 
treatment of mechanically ventilated patients with COVID-19. 
Clin Infect Dis 2020 Jul 11. [online ahead of print]
 63. Lewis TC, Adhikari S, Tatapudi V, et al: A propensity-matched 
cohort study of tocilizumab in patients with coronavirus di-
sease 2019. Crit Care Explor 2020; 2:e0283
 64. Hermine O, Mariette X, Tharaux P-L, et al: Effect of tocili-
zumab vs usual care in adults hospitalized with COVID-19 
and moderate or severe pneumonia. JAMA Intern Med 2020; 
181:32–40
 65. Salvarani C, Dolci G, Massari M, et al: Effect of tocilizumab 
vs standard care on clinical worsening in patients hospitalized 
with COVID-19 pneumonia: A randomized clinical trial. JAMA 
Intern Med 2021; 181:24–31
 66. Gordon AC, Mouncey PR, Al-Beidh F: Interleukin-6 re-
ceptor antagonists in critically ill patients with Covid-19-
preliminary report. MedRX. Published online 2021. doi: 
10.1101/2021.01.07.21249390
 67. Koike T, Harigai M, Inokuma S, et al: Effectiveness and safety of 
tocilizumab: Postmarketing surveillance of 7901 patients with 
rheumatoid arthritis in Japan. J Rheumatol 2014; 41:15–23
 68. Yun H, Xie F, Delzell E, et al: Risks of Herpes Zoster in patients 
with rheumatoid arthritis according to biologic disease modify-
ing therapy. Arthritis Care Res 2015; 67:731–736
 69. Schiff MH, Kremer JM, Jahreis A, et al: Integrated safety in 
tocilizumab clinical trials. Arthritis Res Ther 2011; 13:R141
 70. Sebba A: Tocilizumab: The first interleukin-6-receptor inhibitor. 
Am J Health Syst Pharm 2008; 65:1413–1418
 71. Horby P, Lim WS, Emberson JR, et al: Dexamethasone in hos-
pitalized patients with Covid-19 — preliminary Report. N Engl J 
Med 2021; 384:693–704
 72. Tomazini BM, Maia IS, Cavalcanti AB, et al; COALITION 
COVID-19 Brazil III Investigators: Effect of dexamethasone on 
days alive and ventilator-free in patients with moderate or se-
vere acute respiratory distress syndrome and COVID-19: The 
CoDEX randomized clinical trial. JAMA 2020; 324:1307–1316
 73. Dequin PF, Heming N, Meziani F, et al; CAPE COVID Trial 
Group and the CRICS-TriGGERSep Network: Effect of hydro-
cortisone on 21-day mortality or respiratory support among 
critically ill patients with COVID-19: A randomized clinical trial. 
JAMA 2020; 324:1298–1306
 74. Jeronimo CMP, Farias MEL, Val FFA, et al: Methylprednisolone 
as adjunctive therapy for patients hospitalized with corona-
virus disease 2019 (COVID-19; Metcovid): A randomized, 
double-blind, phase IIb, placebo-controlled trial. Clin Infect Dis 
2021; 72:e373–e381
 75. Kuindersma M, Diaz RR, Spronk PE: Tailored modulation of the 
inflammatory balance in COVID - 19 patients admitted to the 
ICU ?— a viewpoint. Crit Care. 2021; 25:178
 76. World Health Organization: Corticosteroids for COVID-19. 
2020. Available at: https://www.who.int/publications/i/item/
WHO-2019-nCoV-Corticosteroids-2020.1
 77. Wu C, Chen X, Cai Y, et al: Risk factors associated with acute 
respiratory distress syndrome and death in patients with co-
ronavirus disease 2019 pneumonia in Wuhan, China. JAMA 
Intern Med 2020; 180:934–943
 78. Zhou F, Yu T, Du R, et al: Clinical course and risk factors for 
mortality of adult inpatients with COVID-19 in Wuhan, China: 
A retrospective cohort study. Lancet 2020; 395:1054–1062
